Jyong Biotech Ltd. Ordinary Shares (MENS) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MENS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Jyong Biotech Ltd. Ordinary Shares currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $152M | — | — | — | — | — |
| Enterprise Value | $170M | — | — | — | — | — |
| P/E Ratio → | -51.64 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MENS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
MENS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — |
| ROA | -41.3% | -41.3% | -51.8% | -72.9% | -37.7% | -14.9% |
| ROIC | — | — | — | — | — | — |
| ROCE | — | — | — | — | -47.1% | -34.6% |
MENS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $18M ($18M total debt minus $98000 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -1.99 | -1.99 | -3.69 | -3.70 | -2.88 | -2.94 |
MENS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.02x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.19x to 0.02x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.02 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Quick Ratio | 0.02 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Cash Ratio | 0.01 | 0.01 | 0.01 | 0.06 | 0.38 | 0.73 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
MENS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Jyong Biotech Ltd. Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $76M | $76M | $76M | $76M | $72M |
Peer Comparison
Compare MENS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MENSYou | $152M | -51.6 | — | — | — | — | — | — | — |
 AEYE | $100M | -32.4 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $12B | 28.1 | 21.3 | 18.0 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 BTBT | $589M | 9.2 | 8.5 | — | 61.9% | 16.8% | 9.2% | 6.5% | 0.2 |
 CNET | $2M | -0.4 | — | — | 2.9% | -24.3% | -75.4% | -64.7% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See MENS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MENS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MENS vs AEYE
Side-by-side business, growth, and profitability comparison vs AudioEye, Inc..
Start ComparisonMENS — Frequently Asked Questions
Quick answers to the most common questions about buying MENS stock.
What is Jyong Biotech Ltd. Ordinary Shares's P/E ratio?
Jyong Biotech Ltd. Ordinary Shares's current P/E ratio is -51.6x. This places it at the 50th percentile of its historical range.
Is MENS stock overvalued?
Based on historical data, Jyong Biotech Ltd. Ordinary Shares is trading at a P/E of -51.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.